Blood Vessel Maker Strikes $9M Deal To End Investor Action
Biotechnology company Humacyte Inc. and a proposed class of investors have reached a $9 million deal to end claims that the company failed to disclose quality assurance issues at its manufacturing...To view the full article, register now.
Already a subscriber? Click here to view full article